When the going gets tough
Walking into stormy waters may require some chutzpah
Sometimes oncology new product development can be fascinating to watch from the sidelines. There are always up and downs as well as many hurdles and challenges to address.
In a relatively short time the B cell malignancy niche has become a highly crowded space full of tough competitors, with numerous T cell engagers and CAR-T cell therapies already approved and more coming along.
If you’re late to any given market then you will need to stand out as the best-in-class in order to succeed.
There are some companies who execute flawlessly, others well, they can have a rather bad habit of shooting themselves in the foot when least expected…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
